Physiological and pathological phosphorylation of tau by Cdk5

Frontiers in Molecular Neuroscience

Volumn 7, Issue JULY, 2014, Pages

  Kimura, Taeko ^a   Ishiguro, Koichi ^b   Hisanaga, Shin Ichi ^a  

^a TOKYO METROPOLITAN UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Cdk5; FTDP 17; p25; p35; Phosphorylation; Tau; Tauopathy

Indexed keywords

CALPAIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P35; TAU PROTEIN; UBIQUITIN PROTEIN LIGASE E3;

AGING; ALZHEIMER DISEASE; CHROMOSOME 17; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; HYPOXIA; IMMUNOBLOTTING; MUTANT; OXIDATIVE STRESS; PARKINSONISM; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY; WESTERN BLOTTING;

EID: 84904333334     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2014.00065     Document Type: Review

References (130)

1. Absalon, S., Kochanek, D. M., Raghavan, V., and Krichevsky, A. M. (2013). MiR-26b, upregulated in Alzheimer's disease, activates cell cycle entry, tau-phosphorylation, and apoptosis in postmitotic neurons. J. Neurosci. 33, 14645-14659. doi: 10.1523/JNEUROSCI.1327-13.2013
2. Ahlijanian, M. K., Barrezueta, N. X., Williams, R. D., Jakowski, A., Kowsz, K. P., McCarthy, S., et al. (2000). Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. U.S.A. 97, 2910-2915. doi: 10.1073/pnas.040577797
3. Alonso Adel, C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2004). Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 279, 34873-34881. doi: 10.1074/jbc.M405131200
4. Amniai, L., Lippens, G., and Landrieu, I. (2011). Characterization of the AT180 epitope of phosphorylated Tau protein by a combined nuclear magnetic resonance and fluorescence spectroscopy approach. Biochem. Biophys. Res. Commun. 412, 743-746. doi: 10.1016/j.bbrc.2011.08.046
5. Arioka, M., Tsukamoto, M., Ishiguro, K., Kato, R., Sato, K., Imahori, K., et al. (1993). Tau protein kinase II is involved in the regulation of the normal phosphorylation state of tau protein. J. Neurochem. 60, 461-468. doi: 10.1111/j.1471-4159.1993.tb03173.x
6. Asada, A., Saito, T., and Hisanaga, S. (2012). Phosphorylation of p35 and p39 by Cdk5 determines the subcellular location of the holokinase in a phosphorylation-site-specific manner. J. Cell Sci. 125, 3421-3429. doi: 10.1242/jcs.100503
7. Asada, A., Yamamoto, N., Gohda, M., Saito, T., Hayashi, N., and Hisanaga, S. (2008). Myristoylation of p39 and p35 is a determinant of cytoplasmic or nuclear localization of active cyclin-dependent kinase 5 complexes. J. Neurochem. 106, 1325-1336. doi: 10.1111/j.1471-4159.2008.05500.x
8. Avila, J., Gomez de Barreda, E., Engel, T., Lucas, J. J., and Hernandez, F. (2010). Tau phosphorylation in hippocampus results in toxic gain-of-function. Biochem. Soc. Trans. 38, 977-980. doi: 10.1042/BST0380977
9. Barros-Miñones, L., Martin-de-Saavedra, D., Perez-Alvarez, S., Orejana, L., Suquia, V., Goni-Allo, B., et al. (2013). Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate. Biochim. Biophys. Acta 1832, 705-717. doi: 10.1016/j.bbadis.2013.02.002
10. Beaudette, K. N., Lew, J., and Wang, J. H. (1993). Substrate specificity characterization of a cdc2-like protein kinase purified from bovine brain. J. Biol. Chem. 268, 20825-20830.
11. Bertram, L., Lill, C. M., and Tanzi, R. E. (2010). The genetics of Alzheimer disease: back to the future. Neuron 68, 270-281. doi: 10.1016/j.neuron.2010.10.013
12. Bettens, K., Sleegers, K., and Van Broeckhoven, C. (2010). Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum. Mol. Genet. 19, R4-R11. doi: 10.1093/hmg/ddq142
13. Binder, L. I., Frankfurter, A., and Rebhun, L. I. (1985). The distribution of tau in the mammalian central nervous system. J. Cell Biol. 101, 1371-1378. doi: 10.1083/jcb.101.4.1371
14. Brinkkoetter, P. T., Olivier, P., Wu, J. S., Henderson, S., Krofft, R. D., Pippin, J. W., et al. (2009). Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J. Clin. Invest. 119, 3089-3101. doi: 10.1172/JCI37978
15. Chauhan, N. B., Siegel, G. J., and Feinstein, D. L. (2005). Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology 48, 93-104. doi: 10.1016/j.neuropharm.2004.09.014
16. Cohen, P., and Frame, S. (2001). The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2, 769-776. doi: 10.1038/35096075
17. Crowther, R. A., and Goedert, M. (2000). Abnormal tau-containing filaments in neurodegenerative diseases. J. Struct. Biol. 130, 271-279. doi: 10.1006/jsbi.2000.4270
18. Cruz, J. C., and Tsai, L. H. (2004). Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol. Med.10, 452-458. doi: 10.1016/j.molmed.2004.07.001
19. Cruz, J. C., Tseng, H. C., Goldman, J. A., Shih, H., and Tsai, L. H. (2003). Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483. doi: 10.1016/S0896-6273(03)00627-5
20. Davis, R. J. (1993). The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268, 14553-14556.
21. Dehmelt, L., and Halpain, S. (2005). The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 6, 204. doi: 10.1186/gb-2004-6-1-204
22. DeTure, M., Ko, L. W., Easson, C., and Yen, S. H. (2002). Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am. J. Pathol. 161, 1711-1722. doi: 10.1016/S0002-9440(10)64448-3
23. Driver, J. A., Zhou, X. Z., and Lu, K. P. (2014). Regulation of protein conformation by Pin1 offers novel disease mechanisms and therapeutic approaches in Alzheimer's disease. Discov. Med. 17, 93-99.
24. Engmann, O., and Giese, K. P. (2009). Crosstalk between Cdk5 and GSK3β: implications for Alzheimer's disease. Front. Mol. Neurosci. 2:2. doi: 10.3389/neuro.02.002.2009
25. Gauthier-Kemper, A., Weissmann, C., Golovyashkina, N., Sebo-Lemke, Z., Drewes, G., Gerke, V., et al. (2011). The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. J. Cell Biol. 192, 647-661. doi: 10.1083/jcb.201007161
26. Goedert, M., Satumtira, S., Jakes, R., Smith, M. J., Kamibayashi, C., White, C. L. III, et al. (2000). Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. J. Neurochem. 75, 2155-2162. doi: 10.1046/j.1471-4159.2000.0752155.x
27. Goedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J., and Crowther, R. A. (1989). Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393-399.
28. Gómez-Isla, T., Wasco, W., Pettingell, W. P., Gurubhagavatula, S., Schmidt, S. D., Jondro, P. D., et al. (1997). A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. Ann. Neurol. 41, 809-813. doi: 10.1002/ana.410410618
29. Gong, C. X., and Iqbal, K. (2008). Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15, 2321-2328. doi: 10.2174/092986708785909111
30. Gotz, J., Chen, F., Barmettler, R., and Nitsch, R. M. (2001). Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276, 529-534. doi: 10.1074/jbc.M006531200
31. Gotz, J., Schild, A., Hoerndli, F., and Pennanen, L. (2004). Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int. J. Dev. Neurosci. 22, 453-465. doi: 10.1016/j.ijdevneu.2004.07.013
32. Hallows, J. L., Chen, K., DePinho, R. A., and Vincent, I. (2003). Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J. Neurosci. 23, 10633-10644.
33. Han, D., Qureshi, H. Y., Lu, Y., and Paudel, H. K. (2009). Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. J. Biol. Chem. 284, 13422-13433. doi: 10.1074/jbc.M901095200
34. Han, P., Dou, F., Li, F., Zhang, X., Zhang, Y. W., Zheng, H., et al. (2005). Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation. J. Neurosci. 25, 11542-11552. doi: 10.1523/JNEUROSCI.3831-05.2005
35. Hanger, D. P., Anderton, B. H., and Noble, W. (2009). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119. doi: 10.1016/j.molmed.2009.01.003
36. Hardy, J. (2006). Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr. Alzheimer Res. 3, 71-73. doi: 10.2174/156720506775697098
37. Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., and Ihara, Y. (1992). Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J. Biol. Chem. 267, 17047-17054.
38. 205 of human tau. J. Biol. Chem. 277, 44525-44530. doi: 10.1074/jbc.M207426200
39. Hellmich, M. R., Pant, H. C., Wada, E., and Battey, J. F. (1992). Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression. Proc. Natl. Acad. Sci. U.S.A. 89, 10867-10871. doi: 10.1073/pnas.89.22.10867
40. Hisanaga, S., and Endo, R. (2010). Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. J. Neurochem. 115, 1309-1321. doi: 10.1111/j.1471-4159.2010.07050.x
41. Hisanaga, S., Ishiguro, K., Uchida, T., Okumura, E., Okano, T., and Kishimoto, T. (1993). Tau protein kinase II has a similar characteristic to cdc2 kinase for phosphorylating neurofilament proteins. J. Biol. Chem. 268, 15056-15060.
42. Hisanaga, S., Kusubata, M., Okumura, E., and Kishimoto, T. (1991). Phosphorylation of neurofilament H subunit at the tail domain by CDC2 kinase dissociates the association to microtubules. J. Biol. Chem. 266, 21798-21803.
43. Hisanaga, S., Uchiyama, M., Hosoi, T., Yamada, K., Honma, N., Ishiguro, K., et al. (1995). Porcine brain neurofilament-H tail domain kinase: its identification as cdk5/p26 complex and comparison with cdc2/cyclin B kinase. Cell Motil. Cytoskeleton 31, 283-297. doi: 10.1002/cm.970310405
44. Ho, P. I., Ortiz, D., Rogers, E., and Shea, T. B. (2002). Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J. Neurosci. Res. 70, 694-702. doi: 10.1002/jnr.10416
45. Huse, J. T., and Doms, R. W. (2000). Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. Mol. Neurobiol. 22, 81-98. doi: 10.1385/MN:22:1-3:081
46. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al. (1998). Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705. doi: 10.1038/31508
47. Ikeda, M., Shoji, M., Kawarai, T., Kawarabayashi, T., Matsubara, E., Murakami, T., et al. (2005). Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am. J. Pathol. 166, 521-531. doi: 10.1016/S0002-9440(10)62274-2
48. Illenberger, S., Zheng-Fischhofer, Q., Preuss, U., Stamer, K., Baumann, K., Trinczek, B., et al. (1998). The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol. Biol. Cell 9, 1495-1512. doi: 10.1091/mbc.9.6.1495
49. Imahori, K., and Uchida, T. (1997). Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. 121, 179-188.
50. Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley-Whyte, E. T., Frosch, M. P., et al. (2004). Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925-931. doi: 10.1212/01.WNL.0000115115.98960.37
51. Iqbal, K., Alonso Adel, C., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C. X., et al. (2005). Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta 1739, 198-210. doi: 10.1016/j.bbadis.2004.09.008
52. Ishiguro, K., Omori, A., Takamatsu, M., Sato, K., Arioka, M., Uchida, T., et al. (1992). Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett.148, 202-206. doi: 10.1016/0304-3940(92)90839-Y
53. Johnson, G. V., and Stoothoff, W. H. (2004). Tau phosphorylation in neuronal cell function and dysfunction. J. Cell Sci. 117, 5721-5729. doi: 10.1242/jcs.01558
54. Kamei, H., Saito, T., Ozawa, M., Fujita, Y., Asada, A., Bibb, J. A., et al. (2007). Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation. J. Biol. Chem. 282, 1687-1694. doi: 10.1074/jbc.M610541200
55. Kelleher, I., Garwood, C., Hanger, D. P., Anderton, B. H., and Noble, W. (2007). Kinase activities increase during the development of tauopathy in htau mice. J. Neurochem. 103, 2256-2267. doi: 10.1111/j.1471-4159.2007.04930.x
56. Kesavapany, S., Li, B. S., and Pant, H. C. (2003). Cyclin-dependent kinase 5 in neurofilament function and regulation. Neurosignals 12, 252-264. doi: 10.1159/000074627
57. Kimura, T., Tsutsumi, K., Taoka, M., Saito, T., Masuda-Suzukake, M., Ishiguro, K., et al. (2013). Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites. J. Biol. Chem. 288, 7968-7977. doi: 10.1074/jbc.M112.433326
58. Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., and LaFerla, F. M. (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 25, 8843-8853. doi: 10.1523/JNEUROSCI.2868-05.2005
59. Krishnamurthy, P. K., and Johnson, G. V. (2004). Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model. J. Biol. Chem. 279, 7893-7900. doi: 10.1074/jbc.M311203200
60. Kusakawa, G., Saito, T., Onuki, R., Ishiguro, K., Kishimoto, T., and Hisanaga, S. (2000). Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem. 275, 17166-17172. doi: 10.1074/jbc.M907757199
61. Landrieu, I., Leroy, A., Smet-Nocca, C., Huvent, I., Amniai, L., Hamdane, M., et al. (2010). NMR spectroscopy of the neuronal tau protein: normal function and implication in Alzheimer's disease. Biochem. Soc. Trans. 38, 1006-1011. doi: 10.1042/BST0381006
62. Landrieu, I., Smet-Nocca, C., Amniai, L., Louis, J. V., Wieruszeski, J. M., Goris, J., et al. (2011). Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau. PLoS ONE 6:e21521. doi: 10.1371/journal.pone.0021521
63. Lee, K. Y., Qi, Z., Yu, Y. P., and Wang, J. H. (1997). Neuronal Cdc2-like kinases: neuron-specific forms of Cdk5. Int. J. Biochem. Cell Biol. 29, 951-958. doi: 10.1016/S1357-2725(97)00048-4
64. Lee, M. S., Kwon, Y. T., Li, M., Peng, J., Friedlander, R. M., and Tsai, L. H. (2000). Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364. doi: 10.1038/35012636
65. Lee, V. M., Kenyon, T. K., and Trojanowski, J. Q. (2005). Transgenic animal models of tauopathies. Biochim. Biophys. Acta 1739, 251-259. doi: 10.1016/j.bbadis.2004.06.014
66. Lew, J., Beaudette, K., Litwin, C. M., and Wang, J. H. (1992). Purification and characterization of a novel proline-directed protein kinase from bovine brain. J. Biol. Chem. 267, 13383-13390.
67. Lew, J., Huang, Q. Q., Qi, Z., Winkfein, R. J., Aebersold, R., Hunt, T., et al. (1994). A brain-specific activator of cyclin-dependent kinase 5. Nature 371, 423-426. doi: 10.1038/371423a0
68. Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., et al. (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402-405. doi: 10.1038/78078
69. Li, T., Hawkes, C., Qureshi, H. Y., Kar, S., and Paudel, H. K. (2006). Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3β. Biochemistry 45, 3134-3145. doi: 10.1021/bi051635j
70. Lichtenberg-Kraag, B., Mandelkow, E. M., Biernat, J., Steiner, B., Schroter, C., Gustke, N., et al. (1992). Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. Proc. Natl. Acad. Sci. U.S.A. 89, 5384-5388. doi: 10.1073/pnas.89.12.5384
71. Liou, Y. C., Sun, A., Ryo, A., Zhou, X. Z., Yu, Z. X., Huang, H. K., et al. (2003). Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424, 556-561. doi: 10.1038/nature01832
72. Liu, F., Iqbal, K., Grundke-Iqbal, I., and Gong, C. X. (2002). Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3β. FEBS Lett. 530, 209-214. doi: 10.1016/S0014-5793(02)03487-7
73. Lopes, J. P., Oliveira, C. R., and Agostinho, P. (2007). Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. Cell. Mol. Neurobiol. 27, 943-957. doi: 10.1007/s10571-007-9224-3
74. Lu, K. P., Hanes, S. D., and Hunter, T. (1996). A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380, 544-547. doi: 10.1038/380544a0
75. Lu, K. P., and Zhou, X. Z. (2007). The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat. Rev. Mol. Cell Biol. 8, 904-916. doi: 10.1038/nrm2261
76. Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P., and Lu, K. P. (1999). The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399, 784-788. doi: 10.1038/21650
77. Lund, E. T., McKenna, R., Evans, D. B., Sharma, S. K., and Mathews, W. R. (2001). Characterization of the in vitrophosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J. Neurochem. 76, 1221-1232. doi: 10.1046/j.1471-4159.2001.00130.x
78. Mandelkow, E. M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B., and Mandelkow, E. (1995). Tau domains, phosphorylation, and interactions with microtubules. Neurobiol. Aging 16, 355-362; discussion 362-353. doi: 10.1016/0197-4580(95)00025-A
79. Mattson, M. P. (1997). Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77, 1081-1132.
80. Matus, A. (1994). Stiff microtubules and neuronal morphology. Trends Neurosci. 17, 19-22. doi: 10.1016/0166-2236(94)90030-2
81. Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., et al. (1992). A family of human cdc2-related protein kinases. EMBO J. 11, 2909-2917.
82. Minegishi, S., Asada, A., Miyauchi, S., Fuchigami, T., Saito, T., and Hisanaga, S. (2010). Membrane association facilitates degradation and cleavage of the cyclin-dependent kinase 5 activators p35 and p39. Biochemistry 49, 5482-5493. doi: 10.1021/bi100631f
83. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., et al. (1995). Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270, 823-829. doi: 10.1074/jbc.270.2.823
84. Morris, M., Maeda, S., Vossel, K., and Mucke, L. (2011). The many faces of tau. Neuron 70, 410-426. doi: 10.1016/j.neuron
85. Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., et al. (2003). Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565. doi: 10.1016/S0896-6273(03)00259-9
86. Nukina, N., Kosik, K. S., and Selkoe, D. J. (1987). Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc. Natl. Acad. Sci. U.S.A. 84, 3415-3419. doi: 10.1073/pnas.84.10.3415
87. Ono, Y., and Sorimachi, H. (2012). Calpains: an elaborate proteolytic system. Biochim. Biophys. Acta 1824, 224-236. doi: 10.1016/j.bbapap.2011.08.005
88. Otth, C., Concha, I. I., Arendt, T., Stieler, J., Schliebs, R., Gonzalez-Billault, C., et al. (2002). AβPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J. Alzheimers Dis. 4, 417-430.
89. Patrick, G. N., Zhou, P., Kwon, Y. T., Howley, P. M., and Tsai, L. H. (1998). p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J. Biol. Chem. 273, 24057-24064. doi: 10.1074/jbc.273.37.24057
90. Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., and Tsai, L. H. (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622. doi: 10.1038/45159
91. Patzke, H., and Tsai, L. H. (2002). Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J. Biol. Chem. 277, 8054-8060. doi: 10.1074/jbc.M109645200
92. Paudel, H. K., Lew, J., Ali, Z., and Wang, J. H. (1993). Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem.268, 23512-23518.
93. Peterson, D. W., Ando, D. M., Taketa, D. A., Zhou, H., Dahlquist, F. W., and Lew, J. (2010). No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro. Proc. Natl. Acad. Sci. U.S.A. 107, 2884-2889. doi: 10.1073/pnas.0912718107
94. Piedrahita, D., Hernandez, I., Lopez-Tobon, A., Fedorov, D., Obara, B., Manjunath, B. S., et al. (2010). Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer's mice. J. Neurosci. 30, 13966-13976. doi: 10.1523/JNEUROSCI.3637-10.2010
95. Plattner, F., Angelo, M., and Giese, K. P. (2006). The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281, 25457-25465. doi: 10.1074/jbc.M603469200
96. Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., et al. (1998). Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825. doi: 10.1002/ana.410430617
97. Prabakaran, S., Everley, R. A., Landrieu, I., Wieruszeski, J. M., Lippens, G., Steen, H., et al. (2011). Comparative analysis of Erk phosphorylation suggests a mixed strategy for measuring phospho-form distributions. Mol. Syst. Biol. 7, 482. doi: 10.1038/msb.2011.15
98. Qi, Z., Huang, Q. Q., Lee, K. Y., Lew, J., and Wang, J. H. (1995). Reconstitution of neuronal Cdc2-like kinase from bacteria-expressed Cdk5 and an active fragment of the brain-specific activator. Kinase activation in the absence of Cdk5 phosphorylation. J. Biol. Chem. 270, 10847-10854. doi: 10.1074/jbc.270.18.10847
99. Quintanilla, R. A., Orellana, D. I., Gonzalez-Billault, C., and Maccioni, R. B. (2004). Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp. Cell Res. 295, 245-257. doi: 10.1016/j.yexcr.2004.01.002
100. Rosales, J. L., and Lee, K. Y. (2006). Extraneuronal roles of cyclin-dependent kinase 5. Bioessays 28, 1023-1034. doi: 10.1002/bies.20473
101. Saito, T., Ishiguro, K., Onuki, R., Nagai, Y., Kishimoto, T., and Hisanaga, S. (1998). Okadaic acid-stimulated degradation of p35, an activator of CDK5, by proteasome in cultured neurons. Biochem. Biophys. Res. Commun.252, 775-778. doi: 10.1006/bbrc.1998.9739
102. Sakaue, F., Saito, T., Sato, Y., Asada, A., Ishiguro, K., Hasegawa, M., et al. (2005). Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39. J. Biol. Chem. 280, 31522-31529. doi: 10.1074/jbc.M504792200
103. Sengupta, A., Wu, Q., Grundke-Iqbal, I., Iqbal, K., and Singh, T. J. (1997). Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167, 99-105. doi: 10.1023/A:1006883924775
104. Sharma, P., Steinbach, P. J., Sharma, M., Amin, N. D., Barchi, J. J. Jr., and Pant, H. C. (1999). Identification of substrate binding site of cyclin-dependent kinase 5. J. Biol. Chem. 274, 9600-9606. doi: 10.1074/jbc.274.14.9600
105. Shetty, K. T., Link, W. T., and Pant, H. C. (1993). cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization. Proc. Natl. Acad. Sci. U.S.A. 90, 6844-6848. doi: 10.1073/pnas.90.14.6844
106. Shukla, V., Skuntz, S., and Pant, H. C. (2012). Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch. Med. Res. 43, 655-662. doi: 10.1016/j.arcmed.2012.10.015
107. Smet, C., Sambo, A. V., Wieruszeski, J. M., Leroy, A., Landrieu, I., Buee, L., et al. (2004). The peptidyl prolylcis/trans-isomerase Pin1 recognizes the phospho-Thr212-Pro213 site on Tau. Biochemistry 43, 2032-2040. doi: 10.1021/bi035479x
108. Sontag, J. M., and Sontag, E. (2014). Protein phosphatase 2A dysfunction in Alzheimer's disease. Front. Mol. Neurosci. 7:16. doi: 10.3389/fnmol.2014.00016
109. Spillantini, M. G., Bird, T. D., and Ghetti, B. (1998). Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol. 8, 387-402. doi: 10.1111/j.1750-3639.1998.tb00162.x
110. Spillantini, M. G., and Goedert, M. (2013). Tau pathology and neurodegeneration. Lancet Neurol. 12, 609-622. doi: 10.1016/S1474-4422(13)70090-5
111. Takashima, A., Murayama, M., Yasutake, K., Takahashi, H., Yokoyama, M., and Ishiguro, K. (2001). Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci. Lett. 306, 37-40. doi: 10.1016/S0304-3940(01)01864-X
112. Tanemura, K., Murayama, M., Akagi, T., Hashikawa, T., Tominaga, T., Ichikawa, M., et al. (2002). Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J. Neurosci. 22, 133-141.
113. Tang, D., Yeung, J., Lee, K. Y., Matsushita, M., Matsui, H., Tomizawa, K., et al. (1995). An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J. Biol. Chem. 270, 26897-26903. doi: 10.1074/jbc.270.45.26897
114. nck5a complex. Mol. Cell 8, 657-669. doi: 10.1016/S1097-2765(01)00343-4
115. Tatebayashi, Y., Miyasaka, T., Chui, D. H., Akagi, T., Mishima, K., Iwasaki, K., et al. (2002). Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. U.S.A.99, 13896-13901. doi: 10.1073/pnas.202205599
116. Tsai, L. H., Delalle, I., Caviness, V. S. Jr., Chae, T., and Harlow, E. (1994). p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423. doi: 10.1038/371419a0
117. Uchida, T., Ishiguro, K., Ohnuma, J., Takamatsu, M., Yonekura, S., and Imahori, K. (1994). Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase II: its sequence and developmental change in brain. FEBS Lett.355, 35-40. doi: 10.1016/0014-5793(94)01163-X
118. Vandebroek, T., Vanhelmont, T., Terwel, D., Borghgraef, P., Lemaire, K., Snauwaert, J., et al. (2005). Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Biochemistry 44, 11466-11475. doi: 10.1021/bi0506775
119. Vanhelmont, T., Vandebroek, T., De Vos, A., Terwel, D., Lemaire, K., Anandhakumar, J., et al. (2010). Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast. FEMS Yeast Res. 10, 992-1005. doi: 10.1111/j.1567-1364.2010.00662.x
120. Wada, Y., Ishiguro, K., Itoh, T. J., Uchida, T., Hotani, H., Saito, T., et al. (1998). Microtubule-stimulated phosphorylation of tau at Ser202 and Thr205 by cdk5 decreases its microtubule nucleation activity. J. Biochem.124, 738-746. doi: 10.1093/oxfordjournals.jbchem.a022174
121. Watanabe, A., Hasegawa, M., Suzuki, M., Takio, K., Morishima-Kawashima, M., Titani, K., et al. (1993). In vivophosphorylation sites in fetal and adult rat tau. J. Biol. Chem. 268, 25712-25717.
122. Wen, Y., Planel, E., Herman, M., Figueroa, H. Y., Wang, L., Liu, L., et al. (2008). Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 28, 2624-2632. doi: 10.1523/JNEUROSCI.5245-07.2008
123. Wen, Y., Yang, S. H., Liu, R., Perez, E. J., Brun-Zinkernagel, A. M., Koulen, P., et al. (2007). Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim. Biophys. Acta 1772, 473-483. doi: 10.1016/j.bbadis.2006.10.011
124. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351. doi: 10.1016/j.neuron.2007.01.010
125. Yotsumoto, K., Saito, T., Asada, A., Oikawa, T., Kimura, T., Uchida, C., et al. (2009). Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau. J. Biol. Chem. 284, 16840-16847. doi: 10.1074/jbc.M109.003277
126. Yu, Y., Run, X., Liang, Z., Li, Y., Liu, F., Liu, Y., et al. (2009). Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J. Neurochem. 108, 1480-1494. doi: 10.1111/j.1471-4159.2009.05882.x
127. 2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 30, 11938-11950. doi: 10.1523/JNEUROSCI.2357-10.2010
128. Zheng, M., Leung, C. L., and Liem, R. K. (1998). Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J. Neurobiol. 35, 141-159. doi: 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4
129. Zheng, Y. L., Amin, N. D., Hu, Y. F., Rudrabhatla, P., Shukla, V., Kanungo, J., et al. (2010). A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J. Biol. Chem. 285, 34202-34212. doi: 10.1074/jbc.M110.134643
130. Zheng, Y. L., Kesavapany, S., Gravell, M., Hamilton, R. S., Schubert, M., Amin, N., et al. (2005). A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. 24, 209-220. doi: 10.1038/sj.emboj.7600441